IL2RG
Basic information
Region (hg38): X:71107404-71112108
Previous symbols: [ "SCIDX1", "IMD4", "CIDX" ]
Links
Phenotypes
GenCC
Source:
- T-B+ severe combined immunodeficiency due to gamma chain deficiency (Supportive), mode of inheritance: XL
- Omenn syndrome (Supportive), mode of inheritance: AR
- T-B+ severe combined immunodeficiency due to gamma chain deficiency (Strong), mode of inheritance: XL
- T-B+ severe combined immunodeficiency due to gamma chain deficiency (Definitive), mode of inheritance: XL
- T-B+ severe combined immunodeficiency due to gamma chain deficiency (Definitive), mode of inheritance: XL
- T-B+ severe combined immunodeficiency due to gamma chain deficiency (Definitive), mode of inheritance: XL
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Combined immunodeficiency, X-linked | XL | Allergy/Immunology/Infectious | Antiinfectious prophylaxis and early and aggressive treatment of infections is indicated prior to attempts at immune reconstitution; Chronic immunoglobulin therapy may be required even after treatment aimed at immune reconstitution, which is necessary for survival; BMT/HSCT has been described, as has the use of gene therapy in individuals who are not candidates for or who have failed BMT | Allergy/Immunology/Infectious | 2243135; 7883965; 8462096; 9063412; 11517204; 11806989; 20301584; 21184155; 22460439 |
ClinVar
This is a list of variants' phenotypes submitted to
- X-linked severe combined immunodeficiency (67 variants)
- not provided (27 variants)
- Combined immunodeficiency, X-linked (6 variants)
- Combined immunodeficiency, X-linked;X-linked severe combined immunodeficiency (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IL2RG gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 78 | 14 | 93 | |||
missense | 29 | 77 | 19 | 11 | 144 | |
nonsense | 24 | 33 | ||||
start loss | 1 | |||||
frameshift | 32 | 43 | ||||
inframe indel | 4 | |||||
splice donor/acceptor (+/-2bp) | 13 | 18 | ||||
splice region | 3 | 3 | 27 | 33 | ||
non coding | 41 | 13 | 60 | |||
Total | 79 | 53 | 88 | 138 | 38 |
Variants in IL2RG
This is a list of pathogenic ClinVar variants found in the IL2RG region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
X-71107427-CTT-C | X-linked severe combined immunodeficiency | Uncertain significance (Mar 26, 2021) | ||
X-71107430-T-G | Uncertain significance (Sep 10, 2018) | |||
X-71107446-A-G | X-linked severe combined immunodeficiency | Benign (Jan 13, 2018) | ||
X-71107603-C-T | X-linked severe combined immunodeficiency | Uncertain significance (Jan 13, 2018) | ||
X-71107739-G-A | X-linked severe combined immunodeficiency | Likely benign (Nov 13, 2023) | ||
X-71107741-T-C | X-linked severe combined immunodeficiency • IL2RG-related disorder | Uncertain significance (Nov 14, 2023) | ||
X-71107747-GC-AA | X-linked severe combined immunodeficiency | Uncertain significance (Oct 14, 2021) | ||
X-71107748-C-T | X-linked severe combined immunodeficiency | Likely benign (Sep 17, 2023) | ||
X-71107752-A-G | X-linked severe combined immunodeficiency | Uncertain significance (Sep 01, 2021) | ||
X-71107754-G-T | X-linked severe combined immunodeficiency | Likely benign (Mar 26, 2023) | ||
X-71107755-G-T | X-linked severe combined immunodeficiency | Conflicting classifications of pathogenicity (Jul 20, 2023) | ||
X-71107757-G-A | X-linked severe combined immunodeficiency | Likely benign (Oct 17, 2023) | ||
X-71107763-TG-T | X-linked severe combined immunodeficiency | Uncertain significance (Sep 21, 2022) | ||
X-71107765-G-T | X-linked severe combined immunodeficiency | Uncertain significance (Feb 24, 2022) | ||
X-71107766-G-A | X-linked severe combined immunodeficiency | Likely benign (Sep 24, 2023) | ||
X-71107766-G-T | X-linked severe combined immunodeficiency | Likely benign (Oct 14, 2023) | ||
X-71107769-G-A | X-linked severe combined immunodeficiency | Likely benign (Jul 29, 2023) | ||
X-71107769-G-C | X-linked severe combined immunodeficiency | Likely benign (Dec 18, 2022) | ||
X-71107769-G-T | X-linked severe combined immunodeficiency | Likely benign (Apr 08, 2023) | ||
X-71107770-G-A | X-linked severe combined immunodeficiency • Inborn genetic diseases | Uncertain significance (Jan 10, 2024) | ||
X-71107780-G-A | X-linked severe combined immunodeficiency | Likely benign (Jul 16, 2023) | ||
X-71107785-T-C | Combined immunodeficiency, X-linked • X-linked severe combined immunodeficiency | Likely benign (Jan 26, 2024) | ||
X-71107787-C-T | X-linked severe combined immunodeficiency | Likely benign (Jun 14, 2023) | ||
X-71107796-TG-T | X-linked severe combined immunodeficiency | Uncertain significance (May 07, 2023) | ||
X-71107798-G-A | X-linked severe combined immunodeficiency | Likely benign (Jan 31, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
IL2RG | protein_coding | protein_coding | ENST00000374202 | 8 | 4705 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.992 | 0.00848 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.49 | 86 | 135 | 0.639 | 0.0000102 | 2416 |
Missense in Polyphen | 14 | 39.318 | 0.35607 | 731 | ||
Synonymous | 0.0665 | 53 | 53.6 | 0.988 | 0.00000393 | 700 |
Loss of Function | 3.50 | 0 | 14.3 | 0.00 | 0.00000106 | 221 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Common subunit for the receptors for a variety of interleukins.;
- Disease
- DISEASE: Severe combined immunodeficiency X-linked T-cell- negative/B-cell-positive/NK-cell-negative (XSCID) [MIM:300400]: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:7557965, ECO:0000269|PubMed:7668284, ECO:0000269|PubMed:7860773, ECO:0000269|PubMed:7937790, ECO:0000269|PubMed:8027558, ECO:0000269|PubMed:8088810, ECO:0000269|PubMed:8299698, ECO:0000269|PubMed:8401490, ECO:0000269|PubMed:8900089, ECO:0000269|PubMed:9049783, ECO:0000269|PubMed:9150740}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: X-linked combined immunodeficiency (XCID) [MIM:312863]: Less severe form of X-linked immunodeficiency with a less severe degree of deficiency in cellular and humoral immunity than that seen in XSCID. {ECO:0000269|PubMed:7883965, ECO:0000269|PubMed:9399950}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Primary immunodeficiency - Homo sapiens (human);Jak-STAT signaling pathway - Homo sapiens (human);Endocytosis - Homo sapiens (human);Inflammatory bowel disease (IBD) - Homo sapiens (human);HTLV-I infection - Homo sapiens (human);Th17 cell differentiation - Homo sapiens (human);Th1 and Th2 cell differentiation - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Measles - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);JAK-STAT-Core;IL-7 Signaling Pathway;IL-9 Signaling Pathway;IL-4 Signaling Pathway;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Inflammatory Response Pathway;IL-2 Signaling Pathway;Signaling by GPCR;Interleukin-4 and 13 signaling;Interleukin-7 signaling;Signal Transduction;Signaling by Interleukins;il 2 signaling pathway;il-7 signal transduction;il-2 receptor beta chain in t cell activation;il 4 signaling pathway;Cytokine Signaling in Immune system;JAK STAT MolecularVariation 1;Interleukin-9 signaling;Immune System;Interleukin-15 signaling;Interleukin receptor SHC signaling;Interleukin-2 family signaling;IL-2 signaling;IL-7 signaling;IL-4 signaling;SHP2 signaling;JAK STAT MolecularVariation 2;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;JAK STAT pathway and regulation;IL2;IL2-mediated signaling events;Interleukin-2 signaling;IL4;IL-7;G beta:gamma signalling through PI3Kgamma;G-protein beta:gamma signalling;GPCR downstream signalling;IL9;IL2 signaling events mediated by STAT5;Downstream signaling in naïve CD8+ T cells;IL2 signaling events mediated by PI3K;IL4-mediated signaling events;IL12-mediated signaling events;Interleukin-3, 5 and GM-CSF signaling
(Consensus)
Recessive Scores
- pRec
- 0.554
Intolerance Scores
- loftool
- 0.119
- rvis_EVS
- -0.23
- rvis_percentile_EVS
- 36.86
Haploinsufficiency Scores
- pHI
- 0.141
- hipred
- N
- hipred_score
- 0.370
- ghis
- 0.568
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.927
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Il2rg
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; embryo phenotype; no phenotypic analysis (no description of morphological, physiological or behavioral information presented); immune system phenotype; digestive/alimentary phenotype; neoplasm; reproductive system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; respiratory system phenotype;
Zebrafish Information Network
- Gene name
- il2rga
- Affected structure
- mature B cell
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- MAPK cascade;immune response;signal transduction;viral process;cytokine-mediated signaling pathway;interleukin-15-mediated signaling pathway;interleukin-4-mediated signaling pathway;interleukin-2-mediated signaling pathway;interleukin-7-mediated signaling pathway;interleukin-9-mediated signaling pathway;interleukin-21-mediated signaling pathway
- Cellular component
- endosome;cytosol;plasma membrane;integral component of plasma membrane;external side of plasma membrane;membrane;receptor complex
- Molecular function
- cytokine receptor activity;interleukin-2 receptor activity;interleukin-4 receptor activity;interleukin-7 receptor activity;Ras guanyl-nucleotide exchange factor activity;protein binding;cytokine binding;interleukin-2 binding